Genomtec S.A.

Regulatory Filings • Apr 29, 2022

Signing a commercial agreement to sell Genomtec_#174; IDTheManagement Board of Genomtec S.A. (_quot;Issuer_quot;, _quot;Company_quot;) announces thattoday, i.e. 29 April 2022, it signed an agreement with Atropos Ltd., adistributor of laboratory reagents and in vitro diagnostic productsbased in Greece (_quot;Contractor_quot;) for the supply of its flagship productGenomtec_#174; ID (_quot;Agreement_quot;). Under the Agreement, once the Product meetscertain conditions, including receipt of a CE mark, the Contractoragreed to place a minimum order for both the analyzer and therespiratory panel infection reaction card (_quot;Product_quot;) with a total valueof 350 000 EUR in the period of 3 years. The Contractor will have theright of exclusive distribution on the territory of Greece.TheContracting Party is a specialist distributor of molecular biologysolutions with an established position on the market.Pursuant tothe Agreement, upon the delivery of the aforementioned order, theContracting Party may increase the volume of orders beyond the minimumquantity of Products. The remaining provisions of the Agreement do notdiffer from typical conditions for this type of transactions.TheManagement Board of the Company considered the conclusion of theAgreement to be confidential information, because the Contractordeclared that in the case of release of the Product to the market andsatisfactory performance of the device, it will be ready to placefurther orders of greater volume, and therefore there are premises thatthe implementation of the above-mentioned Agreement may have asignificant impact on the future revenue situation of the Issuer, aswell as on the popularization of the technology and the Company'sProduct. Therefore, in the opinion of the Management Board, thisinformation meets the criteria of confidential information within themeaning of Article 7.1 MAR.